Low Back Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major low back pain markets are expected to exhibit a CAGR of 3.7% during 2024-2034.
The low back pain market has been comprehensively analyzed in IMARC's new report titled "Low Back Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Low back pain refers to discomfort or pain in the area of the back between the bottom rib and the buttocks, known as the lumbar region. It can be acute, lasting for a short period, or chronic, persisting for several weeks or longer. Some of the common symptoms include dull or aching pain in the lower back, sharp shooting pain that radiates down the legs, muscle spasms and tightness, reduced range of motion in the lower back, difficulty maintaining proper posture, pain worsened by bending or lifting, and in many cases, tingling, numbness, or weakness in the legs or feet. Diagnosing low back pain typically involves a combination of medical history evaluation, physical examination, and laboratory investigations. A physical exam may include assessing posture, range of motion, and muscle strength as well as performing specific maneuvers to elicit pain or identify potential sources of discomfort. Various diagnostic tests, such as X-rays, MRI scans, CT scans, etc., are performed to visualize the structures of the spine and rule out underlying conditions like herniated discs, spinal stenosis, fractures, etc. In some cases, numerous additional procedures, including blood tests and electromyography (EMG), may be recommended to assess nerve function or detect systemic diseases.
The increasing cases of strain or sprain in the muscles or ligaments of the back due to improper lifting, sudden movements, overexertion, poor posture, etc., are primarily driving the low back pain market. Furthermore, the rising prevalence of sciatica, often caused by spinal stenosis or a herniated disc, resulting in irritation or compression of the sciatic nerve, is creating a positive outlook for the market. Apart from this, the escalating utilization of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to alleviate pain and decrease inflammation associated with low back pain is also bolstering the market growth. Moreover, the widespread adoption of physical therapy, which involves a combination of exercises, stretching, and manual interventions to improve strength, flexibility, and posture, thereby reducing pain as well as promoting healing, is acting as another significant growth-inducing factor. In addition to this, the emerging popularity of transcutaneous electrical nerve stimulation (TENS) therapy that works by stimulating nerves and blocking pain signals from reaching the brain is expected to drive the low back pain market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the low back pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for low back pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the low back pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the low back pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the low back pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current low back pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the low back pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the low back pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the low back pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of low back pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of low back pain by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of low back pain by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with low back pain across the seven major markets?
What is the size of the low back pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of low back pain?
What will be the growth rate of patients across the seven major markets?
Low Back Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for low back pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the low back pain market?
What are the key regulatory events related to the low back pain market?
What is the structure of clinical trial landscape by status related to the low back pain market?
What is the structure of clinical trial landscape by phase related to the low back pain market?
What is the structure of clinical trial landscape by route of administration related to the low back pain market?
The low back pain market has been comprehensively analyzed in IMARC's new report titled "Low Back Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Low back pain refers to discomfort or pain in the area of the back between the bottom rib and the buttocks, known as the lumbar region. It can be acute, lasting for a short period, or chronic, persisting for several weeks or longer. Some of the common symptoms include dull or aching pain in the lower back, sharp shooting pain that radiates down the legs, muscle spasms and tightness, reduced range of motion in the lower back, difficulty maintaining proper posture, pain worsened by bending or lifting, and in many cases, tingling, numbness, or weakness in the legs or feet. Diagnosing low back pain typically involves a combination of medical history evaluation, physical examination, and laboratory investigations. A physical exam may include assessing posture, range of motion, and muscle strength as well as performing specific maneuvers to elicit pain or identify potential sources of discomfort. Various diagnostic tests, such as X-rays, MRI scans, CT scans, etc., are performed to visualize the structures of the spine and rule out underlying conditions like herniated discs, spinal stenosis, fractures, etc. In some cases, numerous additional procedures, including blood tests and electromyography (EMG), may be recommended to assess nerve function or detect systemic diseases.
The increasing cases of strain or sprain in the muscles or ligaments of the back due to improper lifting, sudden movements, overexertion, poor posture, etc., are primarily driving the low back pain market. Furthermore, the rising prevalence of sciatica, often caused by spinal stenosis or a herniated disc, resulting in irritation or compression of the sciatic nerve, is creating a positive outlook for the market. Apart from this, the escalating utilization of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to alleviate pain and decrease inflammation associated with low back pain is also bolstering the market growth. Moreover, the widespread adoption of physical therapy, which involves a combination of exercises, stretching, and manual interventions to improve strength, flexibility, and posture, thereby reducing pain as well as promoting healing, is acting as another significant growth-inducing factor. In addition to this, the emerging popularity of transcutaneous electrical nerve stimulation (TENS) therapy that works by stimulating nerves and blocking pain signals from reaching the brain is expected to drive the low back pain market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the low back pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for low back pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the low back pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the low back pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the low back pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current low back pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the low back pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the low back pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the low back pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of low back pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of low back pain by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of low back pain by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with low back pain across the seven major markets?
What is the size of the low back pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of low back pain?
What will be the growth rate of patients across the seven major markets?
Low Back Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for low back pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the low back pain market?
What are the key regulatory events related to the low back pain market?
What is the structure of clinical trial landscape by status related to the low back pain market?
What is the structure of clinical trial landscape by phase related to the low back pain market?
What is the structure of clinical trial landscape by route of administration related to the low back pain market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LOW BACK PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LOW BACK PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LOW BACK PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 LOW BACK PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LOW BACK PAIN - UNMET NEEDS
10 LOW BACK PAIN - KEY ENDPOINTS OF TREATMENT
11 LOW BACK PAIN - MARKETED PRODUCTS
11.1 List of Low Back Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 LOW BACK PAIN - PIPELINE DRUGS
12.1 List of Low Back Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. LOW BACK PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LOW BACK PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LOW BACK PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Low Back Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Low Back Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Low Back Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Low Back Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Low Back Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Low Back Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Low Back Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Low Back Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Low Back Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Low Back Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Low Back Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Low Back Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Low Back Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Low Back Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Low Back Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Low Back Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Low Back Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Low Back Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Low Back Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Low Back Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Low Back Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Low Back Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Low Back Pain - Access and Reimbursement Overview
16 LOW BACK PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LOW BACK PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LOW BACK PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LOW BACK PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LOW BACK PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LOW BACK PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 LOW BACK PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LOW BACK PAIN - UNMET NEEDS
10 LOW BACK PAIN - KEY ENDPOINTS OF TREATMENT
11 LOW BACK PAIN - MARKETED PRODUCTS
11.1 List of Low Back Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 LOW BACK PAIN - PIPELINE DRUGS
12.1 List of Low Back Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. LOW BACK PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LOW BACK PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LOW BACK PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Low Back Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Low Back Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Low Back Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Low Back Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Low Back Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Low Back Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Low Back Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Low Back Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Low Back Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Low Back Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Low Back Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Low Back Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Low Back Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Low Back Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Low Back Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Low Back Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Low Back Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Low Back Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Low Back Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Low Back Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Low Back Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Low Back Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Low Back Pain - Access and Reimbursement Overview
16 LOW BACK PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LOW BACK PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LOW BACK PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
